✦ LIBER ✦

Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial

✍ Scribed by Milton G. Mutchnick; Henry D. Appelman; H. T. Chung; Emma Aragona; Tej P. Gupta; Glen D. Cummings; Jeanne G. Waggoner; Jay H. Hoofnagle; David A. Shafritz

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 828 KB
Volume: 14
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.1840140302

No coin nor oath required. For personal study only.

✦ Synopsis

Chronic hepatitis B is a severe and frequently progressive disease. We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg. Seven patients received thymosin fraction 5 or thymosin-alpha 1 and five patients received placebo twice weekly for 6 mo. By the conclusion of the study (1 yr), serum aminotransferase levels had improved significantly in thymosin-treated patients, but not in the placebo group. Six (86%) of the thymosin treated patients and one (20%) patient given placebo cleared hepatitis B virus DNA from serum (p less than 0.04, Fisher's exact test). After treatment, replicative forms of hepatitis B virus DNA were present in the liver specimens of four of five placebo-treated patients but in only one of seven thymosin-treated patients (p less than 0.04, Fisher's exact test). Response to thymosin therapy was associated with significant improvements in peripheral blood lymphocyte and CD3 and CD4 counts and in in vitro production of interferon-gamma over initial values. No significant side effects were observed in patients given thymosin or in placebo-treated patients. Clinical, biochemical and serological improvement in patients responding to thymosin were sustained during 26 +/- 3 mo of follow-up. The results of this pilot trial suggest that thymosin therapy promotes disease remission and cessation of hepatitis B virus replication in patients with chronic viral infection.

📜 SIMILAR VOLUMES

Efficacy of thymosin α1 in patients with

Efficacy of thymosin α1 in patients with chronic hepatitis B: A randomized, controlled trial

✍ Rong-Nan Chien; Yun-Fan Liaw; Tse-Ching Chen; Chau-Ting Yeh; I.-Shyan Sheen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 1 views

Thymosin ␣ 1 (T␣) is an immune modifier that has been shown in a pilot study to be effective for chronic hepatitis B; this requires confirmation. Ninety-eight patients with clinicopathologically proven chronic hepatitis B were randomly allocated to 3 groups: 1) group A received a 26-week course of T

Combination therapy with thymosin α1 and

Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial

✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr

A randomized controlled trial of thymosi

A randomized controlled trial of thymosin-α1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody—and hepatitis B virus DNA—positive chronic hepatitis B

✍ P Andreone; C Cursaro; A Gramenzi; C Zavaglia; I Rezakovic; E Altomare; R Severi 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 1 views

ment for anti-HBe-positive chronic hepatitis. The benefit It has recently been shown that thymosin-a 1 (T-a 1 ), a of this agent in producing long-term inhibition of HBV synthetic polypeptide of thymic origin, is able to proreplication must be confirmed by future trials. (HEPAmote disease remission

Double-blind, randomized controlled tria

Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B

✍ Artillo, Santiago; Pastore, Giuseppe; Alberti, Alfredo; Milella, Michelle; Santa 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB 👁 1 views

Pilot studies have demonstrated that recombinant interleukin 2 (rIL-2) has an indirect antiviral activity against hepatitis B virus, but the minimal dose of rIL-2 for induction of this effect was not defined. The aim of the study was to ascertain the most efficient dose of rIL-2 for induction of the

Interferon-α and zidovudine combination

Interferon-α and zidovudine combination therapy for chronic hepatitis B: Results of a randomized, placebo-controlled trial

✍ Harry L. A. Janssen; Luuk Berk; Rudolf A. Heijtink; Fiebo J. W. Ten Kate; Solko 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 630 KB

Interferon-a therapy leads to HBeAg seroconversion in only one third of patients with chronic hepatitis B. In an attempt to increase the seroconversion rate, we investigated the combination of interferon-a and zidovudine in a subset of patients with presumably low response rates for interferon-a mon

Treatment of chronic hepatitis C with co

Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial

✍ M J Tong; K R Reddy; W M Lee; P J Pockros; J C Hoefs; E B Keeffe; F B Hollinger; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB 👁 2 views

AND THE CONSENSUS INTERFERON STUDY GROUP 15 tion. Efficacy was assessed by normalization of serum alanine This multicenter, randomized, controlled, double-blind, transaminase (ALT) concentration and decrease in serum hepphase III study in 704 patients with chronic hepatitis C infecatitis C virus (HC